FDA Slaps Replidyne With Faropenem Warning
This article was originally published in The Pink Sheet Daily
Executive Summary
Dubious trials were done several years ago by Bayer, Replidyne tells “The Pink Sheet” DAILY.
You may also be interested in...
Replidyne Shelves Faropenem Program
Potential partners may have been scared off by challenging trial designs, analyst tells “The Pink Sheet” DAILY.
Replidyne Shelves Faropenem Program
Potential partners may have been scared off by challenging trial designs, analyst tells “The Pink Sheet” DAILY.
FDA Anti-Infective Drugs Advisory Committee To Review Two Antibiotics
Johnson & Johnson’s ceftobiprole and Theravance’s telavancin will be discussed Feb. 27-28.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: